Health Care/Hospital
ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'
* IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. * Niclosamide-based metabolic anticancer drug aims to block signaling pathways that allow cancer cells to evade anticancer effects, potentially solving the issue ...
2024-07-11 14:07
1953
Official Swiss delegation experiences new frontiers in art tech at HKBU
HONG KONG, July 11, 2024 /PRNewswire/ -- A senior Swiss delegation led by Mr Guy Parmelin, Swiss Federal Councillor and Head of the Federal Department of Economic Affairs, Education and Research, visited Hong KongBaptist University (HKBU) on 5 July. The delegation was able to partake in the premi...
2024-07-11 13:34
1542
Kangsters Unveils Revolutionary Treadmills at Rollettes Experience 2024: Celebrating Innovation and Empowerment
LOS ANGELES, July 10, 2024 /PRNewswire/ -- Kangsters, the pioneering South Korean adaptive tech startup, proudly announces its participation in the Rollettes Experience 2024. This renowned event, now celebrating its 11th anniversary, will be held fromJuly 11-14 at the Sheraton Hotel in Los Angele...
2024-07-11 00:00
2144
Snorles GenioFlex: The Innovative Daytime Solution for Snoring Management Now Launched on Indiegogo
HONG KONG, July 10, 2024 /PRNewswire/ -- Snorles, a leading innovator in sleep technology, is excited to announce the launch of its latest product, GenioFlex. Snorles created to address snoring issues and promote overall health and well-being, GenioFlex offers a fresh approach to managing snoring...
2024-07-10 20:02
1701
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year t...
2024-07-10 13:30
3391
KOSÉ, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells
Demonstration testing of "my own" beauty products PALO ALTO, Calif., July 9, 2024 /PRNewswire/ -- KOSÉ Corporation (Headquarters: Chuo-ku,Tokyo; President: Kazutoshi Kobayashi), I Peace, Inc. (Headquarters:Palo Alto, California, USA; Founder & CEO: Koji Tanabe), and Reju, Inc. (Headquarters: Min...
2024-07-09 23:00
2031
Bestqool Pro Series Redefines the Standard of Red Light Therapy Devices: Cutting-Edge Technology Undergone the Third-party Laboratory Diagnostic Testing
NEW YORK, July 9, 2024 /PRNewswire/ -- Bestqool, as one of the industry's top makers of innovative red light therapy devices for over six years, in recent months proactively sent their Pro Series devices to LightLab International Allentown LLC, a reputable third-party laboratory in the US. Bestqo...
2024-07-09 21:00
2195
Goodix Launches Its Latest Automotive-Grade Bluetooth LE SoC and CGM Solutions at electronica China 2024
SHENZHEN, China, July 8, 2024 /PRNewswire/ -- Goodix Technology today unveiled its Continuous Glucose Monitoring (CGM) solutions and automotive-grade Bluetooth LE SoC at the electronicaChina 2024. Demonstrating a dedication to innovation in sensing and wireless technology, Goodix showcased its la...
2024-07-08 22:00
2197
Porton J-STAR and Enabling Technologies Consortium Collaboration on Co-processing Platform Technology Development
CHONGQING, China, July 8, 2024 /PRNewswire/ -- Porton J-STAR today announced
that Enabling Technologies Consortium (ETC) has awarded a two-year contract to
J-STAR to collaborate on "Co-processing Platform Technology."
2024-07-08 22:00
1491
Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®
* Tergase® poised to capture a fair share of the global hyaluronidase market.
DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc.
2024-07-08 21:00
2017
DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer's Disease
BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer's disease (AD). AD is the most frequent ...
2024-07-08 17:23
1432
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME
* The nomination of novel Lp-PLA2 inhibitor DPT0415 for the treatment of DR & DME. * DPT0415 is a highly potent, selective and safe Lp-PLA2 inhibitor with sufficient target engagement at a dose of 0.3 mpk and robust efficacy in the STZ-induced rat DR model. * This project further validates ...
2024-07-08 17:00
1461
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its ...
2024-07-08 16:28
1473
BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial
SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-blind, placebo-controlled, dose-ranging phase 2 clinical tri...
2024-07-08 13:41
1592
Hainan Free Trade Port deepens cooperation with Switzerland
HAIKOU, China, July 7, 2024 /PRNewswire/ -- A report from Hainan International
Media Center (HIMC):
2024-07-07 22:36
2659
Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 for Treatment of AR+ Triple-Negative Breast Cancer (TNBC)
CHENGDU, China, July 5, 2024 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (688302.SH), a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for HP518, an investi...
2024-07-05 21:00
4743
IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy
SHANGHAI and NANJING, China and SAN JOSE, Calif., July 5, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", H...
2024-07-05 16:30
4136
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
SAN FRANCISCO, July 5, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar), which is a synthetic biology-driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that ...
2024-07-05 16:07
1476
Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia
HANGZHOU, China, July 5, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that the company has completed the enrollment in the Phase1b/2a trial ...
2024-07-05 15:56
3470
Bloomage Chairperson Zhao Yan Speaks on Sustainable Innovation at the 2024 Summer Davos Forum
PARSIPPANY, N.J., July 4, 2024 /PRNewswire/ -- Zhao Yan, Chairperson and CEO of
Bloomage, attended the 15th Annual Meeting of the New Champions (Summer Davos
Forum) organized by the World Economic Forum to offer insights on navigating
the current uncertainties in the global economy.
2024-07-04 21:00
1673
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5203
